Authors

Squamous Cell Carcinoma of the Kidney: A Large Case Series

Syed Arslan Shehzad Shah, MD, and colleagues present findings from a broad investigation into this rare neoplasm of the kidney, including data on patient demographics and mean survival.

Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy

Khaled W. Kabbara, MD, and colleagues, research treatment options for cholangiocarcinoma.

7 TiP Randomized, Multicenter, International Phase 3 ARTEST Study to Evaluate the Efficacy and Safety of Enobosarm Versus Active Control for the Treatment of AR+, ER+, HER2– Metastatic Breast Cancer in Patients Who Previously Received an Estrogen-Blocking Agent and CDK4/6 Inhibitor

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

34 12-Year Review of Surgical Outcomes in Implant-Based Reconstructions With Modification and Optimization of Mastectomy Flap Geometry and Soft Tissue Quality: a Retrospective Review of 900 Implant-Based Breast Reconstructions

An Embarrassment of Riches Treatment Sequencing in Gastrointestinal Cancers

Laura W. Goff, MD, MSCI, MMHC, discusses the onslaught of treatment sequencing available in gastrointestinal cancer.

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.

6 Real-world Adherence and Persistence With Palbociclib Treatment Among Insured Patients With HR+/HER2– Metastatic Breast Cancer in the United States

69 The Importance of Tri-Modality Therapy for De Novo Stage IV Invasive Lobular Carcinoma (ILC) Presenting With Bone-Only Metastases

14 Outcomes With First-Line (1L) Ribociclib (RIB) + Endocrine Therapy (ET) vs Physician’s Choice Combination Chemotherapy (combo CT) by Age in Pre/Perimenopausal Patients (pts) With Aggressive HR+/HER2– Advanced Breast Cancer (ABC): A Subgroup Analysis of the RIGHT Choice Trial

5 Treatment Patterns and Clinical Outcomes in Patients Receiving Palbociclib Combinations as First- Line Treatment for Advanced or Metastatic Breast Cancer in Realworld Settings in Argentina and Colombia: Results from the IRIS Study

31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

8 Using a Liquid Biopsy Mediated Approach for Determination of HER2 Amplification Status in Patient Samples

45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery

21 TiP Pivotal Phase 3, Randomized Controlled Trial Evaluating the Safety and Efficacy of Aminolevulinic Acid for the Real-time Visualization of Cancer Through Fluorescent Imaging During Breast-Conserving Surgery

102 Novel Prognostic and Predictive Locoregional Biosignature for Risk Stratification of Early-Stage Hormone Receptor–Positive Breast Cancer

44 Implementation of a Novel Radiopaque Filament Marker at a Single Breast Cancer Surgery Center

17 TROPION-Breast05: A Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Versus Chemotherapy (CT) Plus Pembrolizumab in Patients (pts) With PD-L1–Positive Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer (TNBC)

41 A Case Series of Sarcomas

Casting a Wide NET: When Is the Optimal Time for 177Lu-Dotatate Treatment?

Given that well-differentiated grade 3 NETs are relatively new, standard-of-care treatment options are undefined.

96 Elacestrant Real-World Progression-Free Survival of Adult Patients With ER+/HER2–, Advanced Breast Cancer: A Retrospective Analysis Using Insurance Claims in the United States

Product Profile of Amivantamab Plus Chemotherapy in EGFR Exon 20+ NSCLC

Tammy McClellan, PharmD, discusses the use of amivantamab plus chemotherapy in patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

56 Paternal vs Maternal Inheritance of a BRCA Mutation: Is There a Difference in Presentation and Stage of Breast Cancer at Diagnosis?

30 Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and Combined With Abemaciclib, for Patients with ER+, HER2– Advanced Breast Cancer, Pretreated With Endocrine Therapy: Results of the Phase 3 EMBER-3 Trial

5 Feasibility of WF-OCT as an Adjunct to Intraoperative Specimen X-ray for Breast Conservation Surgical Specimens

28 Case Series: Imaging Appearance of Non–Breast Cancer Solid Masses in the Male Breast

Bridging the Gaps: Taking Care of the Whole Person

Sheila Lahijani, MD, FACLP, gives her perspective on the need for psycho-oncologists to help patients during their cancer journeys.

24 Patient Preferences for CDK4/6 Inhibitor Treatments in HR+/HER2– Early Breast Cancer: A Discrete Choice Survey Study